Cart
sales@molnova.com
TG-46
CAS No. 936091-15-5
TG-46( —— )
Catalog No. M33688 CAS No. 936091-15-5
TG-46 (TG46) inhibits JAK2, FLT3, RET, JAK3 and can be used to study glaucoma.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 296 | Get Quote |
|
| 5MG | 409 | Get Quote |
|
| 10MG | 618 | Get Quote |
|
| 25MG | 1021 | Get Quote |
|
| 50MG | 1546 | Get Quote |
|
| 100MG | 2286 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameTG-46
-
NoteResearch use only, not for human use.
-
Brief DescriptionTG-46 (TG46) inhibits JAK2, FLT3, RET, JAK3 and can be used to study glaucoma.
-
DescriptionJAK-IN-35 (compound TG46) is a JAK2 inhibitor that canb be used in cancer research.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetJAK
-
RecptorJAK | FLT
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number936091-15-5
-
Formula Weight510.65
-
Molecular FormulaC26H34N6O3S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCc1cnc(Nc2ccc(CN3CCOCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Wenge Zhu, et al. Combination therapy for treating cancer. Patent WO2018187485A1.
molnova catalog
related products
-
Butyzamide
Butyzamide is an effective and oral Mpl activator. It is a novel non-peptide-based molecule with antagonistic effects on thrombopoietin (TPO) receptors, which promotes proliferation of human Mpl (hMpl) expression and mouse pro B cell line Ba/F3.
-
PF-04965842
PF-04965842 (Abrocitinib, PF04965842) is a potent, selective, orally bioavailable JAK1 inhibitor with IC50 of 29 nM.
-
JAK2-IN-7
JAK2-IN-7 is a selective JAK2 inhibitor with IC50s of 3, 11.7, and 41 nM for JAK2, SET-2, and Ba/F3V617F cells, respectively. JAK2-IN-7 possesses >14-fold selectivity over JAK1, JAK3, FLT3. JAK2-IN-7 stimulates cell cycle arrest in the G0/G1 phase and induces tumor cellapoptosis. Antitumor activities.
